Search | TVST | ARVO Journals

Showing 1 – 20 of 35

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2024

A Phase II, prospective, multi-center, single masked, randomized, controlled, study to determine the efficacy and safety of dexamethasone ophthaLmic suspension Eye drOps in uveitic and Post-surgicAl maculaR eDema: The LEOPARD Study

Hareem Khan; Muhammad Sohail Halim; Chris Or; Robert Wang; Victor H Gonzalez; Edmund Tsui; Pouya Dayani; Quan Dong Nguyen

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):3127.

ARVO Annual Meeting Abstract June 2024

Photobiomodulation Using the Valeda Multiwavelength Light Delivery System Demonstrates Significant Reduction in Risk for Vision Loss and Onset of Geographic Atrophy in Dry Age-Related Macular Degeneration

Todd Schneiderman; Victor H Gonzalez; David S Boyer; Richard B Rosen; Samantha Xavier; Allen Hu; David Warrow; Eleonora M Lad; Diana V Do; Allen Ho; Glenn J Jaffe; Marion Ronit Munk; Cindy Croissant; Stephanie Tedford; Rene Ruckert; Clark Tedford

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):379.

ARVO Annual Meeting Abstract June 2023

Diagnostic Accuracy of the Flicker Full Field Electroretinogram to Detect Retinal Dysfunction in Diabetic Retinopathy: Frequency Domain Parameter Correlations

Sean Monday; Andrew Tirsi; Matthew Emmer; Stephanie Tedford; Anthony Fontanetta; Victor H Gonzalez

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):552.

ARVO Annual Meeting Abstract June 2023

Efficacy and safety of MCO-010 optogenetic therapy for vision restoration in patients with severe vision loss due to retinitis pigmentosa: A phase 2b randomized, sham-controlled, multi-center, multi-dose, double-masked clinical trial (RESTORE)

David S Boyer; Lance Bergstrom; Andres Emanuelli; Victor H Gonzalez; Charles Clifton Wykoff; Sunil Gupta; David S Liao; Vitaliy Zak; Sai H Chavala; Samar Mohanty; subrata bataybal; Jody Piltz-Seymour; Ananta Ayyagari; John Koester; Aaron Osborne

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):5443.

ARVO Annual Meeting Abstract June 2023

MCO-010 intravitreal optogenetic therapy in Stargardt disease. 6-month outcomes from the Phase 2 STARLIGHT trial

Victor H Gonzalez; Byron L Lam; Vitaliy Zak; Samar Mohanty; subrata bataybal; Jean Chang; Ananta Ayyagari; Sai H Chavala; Jody Piltz-Seymour; John Koester; Aaron Osborne

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):3546.

ARVO Annual Meeting Abstract June 2022

LIGHTSITE III (Interim Analysis): Evaluation of Multiwavelength Photobiomodulation in Dry Age-Related Macular Degeneration Using the LumiThera Valeda Light Delivery System

Marion Ronit Munk; Victor H. Gonzalez; David S Boyer; Diana V Do; Samantha Xavier; Allen Hu; Richard B Rosen; Eleonora Lad; Todd Schneiderman; Allen C Ho; Glenn Jaffe; David Warrow; Stephanie Tedford; Cindy Croissant; Rene Ruckert; clark tedford

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):379 – F0210.

ARVO Annual Meeting Abstract June 2022

Two Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Studies of the Local Anesthetic Effect of Articaine Sterile Topical Ophthalmic Solution 8% (AG-920)

Victor H Gonzalez; Gary D Novack; David Wirta; Martin Uram; Audrey Schupp; Michelle C Widmann

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):334 – F0165.

ARVO Annual Meeting Abstract June 2022

End Point Management (EPM) in Clinically Significant Diabetic Macular Edema (CSME)

Noor-Ul-Ain Shekoh; Tooba Fatima; Quratulain Shekoh; Victor H. Gonzalez

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):3742 – F0163.

Clinical Trials December 2021

Safety and Tolerability of Intravitreal Carotuximab (DE-122) in Patients With Persistent Exudative Age-Related Macular Degeneration: A Phase I Study

PDF

Victor H. Gonzalez; Brian Berger; Roger Goldberg; Carmelina M. Gordon; Rahul N. Khurana; Raymund Angeles; Naveed Shams
TAGS: anti-vascular endothelial growth factor therapy, exudative age-related macular degeneration, persistence, phase 1 clinical trials, safety, intravitreal injections, cohort studies, endoglin, eye
Trans. Vis. Sci. Tech.. 2021; 10(14):27. https://doi.org/10.1167/tvst.10.14.27

Includes: Supplemental Content

ARVO Annual Meeting Abstract June 2021

Safety of multiple intravitreal injections of ocriplasmin in subjects with non–proliferative diabetic retinopathy (NPDR): Results of the CIRCLE study.

Mahi Muqit; Ramin Tadayoni; J Hamouz; Victor H Gonzalez; Javier Montero; David Scales; Geeta V Menon; Prema Abraham; Timothy L Jackson; Ivan Fiser; Petra Kozma-Wiebe

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):1083.

ARVO Annual Meeting Abstract June 2020

Genetic and Ocular Imaging Analysis in Patients with Retinitis Pigmentosa: Case Series

AGUSTIN LORIA; Walter I. Rivera; Alice Behrens; Victor H. Gonzalez

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):3049.

ARVO Annual Meeting Abstract June 2020

Evaluation of Cystoid Macular Edema and Inner-segment-outer-segment Span Loss in Predicting Visual Progression in Patients with Retinitis Pigmentosa

Alice Behrens; AGUSTIN LORIA; Walter I. Rivera; Victor H Gonzalez

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):3050.

ARVO Annual Meeting Abstract June 2020

Evaluation of Safety Outcomes of Pars Plana Vitrectomy Surgery using the Hypersonic Vitrector System: Case Series.

Walter I. Rivera; Agustin Loria; Alice Behrens; Victor H. Gonzalez

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):3731.

ARVO Annual Meeting Abstract July 2019

First real world analysis of safety in 0.19 mg fluocinolone acetonide (FAc, ILUVIEN) implant treated eyes receiving supplemental ocular steroid injection for diabetic macular edema (DME)

Victor H Gonzalez

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):2636.

ARVO Annual Meeting Abstract July 2019

Choroidal Thickness in Central Serous Retinopathy in Patients with Active and Inactive Disease.

Walter I Rivera; Sarah E Miller; Rashed Alhabshan; Victor H Gonzalez

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):4328.

ARVO Annual Meeting Abstract July 2018

The prevalence of diabetes mellitus and diabetic retinopathy in the Rio Grande Valley: A demographics report

Donald C C Meadows; Hamzah Khalaf; Matthew P Johnson; Victor H Gonzalez

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):1039.

ARVO Annual Meeting Abstract July 2018

The extent and visual acuity outcome in disorganization of the inner retinal layers following resolution of macular edema under different treatment modalities

Mahdi Rostamizadeh; Hamzah Khalaf; Victor H Gonzalez

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):4261.

ARVO Annual Meeting Abstract July 2018

Optimization of diabetic macular edema (DME) therapy following 0.2 µg/day fluocinolone acetonide (FAc) implant administration

Victor H Gonzalez

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):4848.

ARVO Annual Meeting Abstract July 2018

Subcutaneous Administration of AKB-9778, a Tie2 Activator, Reduces IOP in Patients with Diabetic Retinopathy

Mitchell G Brigell; Victor H Gonzalez; Darren J Bell; Arshad M. Khanani; Barbara Withers; Laura Gambino; Peter A Campochiaro; Kevin G Peters; Steve Pakola

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):1252.

ARVO Annual Meeting Abstract July 2018

Foveal Avascular Zone in high risk proliferative diabetic retinopathy treated with intravitreal aflibercept injection (ELYSIAN)

Hamzah Khalaf; Mahdi Rostamizadeh; Victor H Gonzalez

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):2789.

1 2

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

A Phase II, prospective, multi-center, single masked, randomized, controlled, study to determine the efficacy and safety of dexamethasone ophthaLmic suspension Eye drOps in uveitic and Post-surgicAl maculaR eDema: The LEOPARD Study

Photobiomodulation Using the Valeda Multiwavelength Light Delivery System Demonstrates Significant Reduction in Risk for Vision Loss and Onset of Geographic Atrophy in Dry Age-Related Macular Degeneration

Diagnostic Accuracy of the Flicker Full Field Electroretinogram to Detect Retinal Dysfunction in Diabetic Retinopathy: Frequency Domain Parameter Correlations

Efficacy and safety of MCO-010 optogenetic therapy for vision restoration in patients with severe vision loss due to retinitis pigmentosa: A phase 2b randomized, sham-controlled, multi-center, multi-dose, double-masked clinical trial (RESTORE)

MCO-010 intravitreal optogenetic therapy in Stargardt disease. 6-month outcomes from the Phase 2 STARLIGHT trial

LIGHTSITE III (Interim Analysis): Evaluation of Multiwavelength Photobiomodulation in Dry Age-Related Macular Degeneration Using the LumiThera Valeda Light Delivery System

Two Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Studies of the Local Anesthetic Effect of Articaine Sterile Topical Ophthalmic Solution 8% (AG-920)

End Point Management (EPM) in Clinically Significant Diabetic Macular Edema (CSME)

Safety and Tolerability of Intravitreal Carotuximab (DE-122) in Patients With Persistent Exudative Age-Related Macular Degeneration: A Phase I Study

Safety of multiple intravitreal injections of ocriplasmin in subjects with non–proliferative diabetic retinopathy (NPDR): Results of the CIRCLE study.

Genetic and Ocular Imaging Analysis in Patients with Retinitis Pigmentosa: Case Series

Evaluation of Cystoid Macular Edema and Inner-segment-outer-segment Span Loss in Predicting Visual Progression in Patients with Retinitis Pigmentosa

Evaluation of Safety Outcomes of Pars Plana Vitrectomy Surgery using the Hypersonic Vitrector System: Case Series.

First real world analysis of safety in 0.19 mg fluocinolone acetonide (FAc, ILUVIEN) implant treated eyes receiving supplemental ocular steroid injection for diabetic macular edema (DME)

Choroidal Thickness in Central Serous Retinopathy in Patients with Active and Inactive Disease.

The prevalence of diabetes mellitus and diabetic retinopathy in the Rio Grande Valley: A demographics report

The extent and visual acuity outcome in disorganization of the inner retinal layers following resolution of macular edema under different treatment modalities

Optimization of diabetic macular edema (DME) therapy following 0.2 µg/day fluocinolone acetonide (FAc) implant administration

Subcutaneous Administration of AKB-9778, a Tie2 Activator, Reduces IOP in Patients with Diabetic Retinopathy

Foveal Avascular Zone in high risk proliferative diabetic retinopathy treated with intravitreal aflibercept injection (ELYSIAN)

To View More...

You must be signed into an individual account to use this feature.